| For the past eight years, M.
D. Anderson has ranked number one in cancer care in "Americas
Best Hospitals" survey published by U.S. News & World
Report.
Nearly 85,000 people per year, including 29,000 new patients,
seek the highest quality care that has made M. D. Anderson so
widely respected.
More than 11,000 patients per year participate in therapeutic
clinical research exploring novel treatments, the largest such
program in the nation.
Important scientific knowledge gained in the laboratory is rapidly
translated into clinical care at M. D. Anderson. The research
program is considered one of the most productive in the world
aimed solely at cancer.
The Nellie B. Connally Breast Center at M. D. Anderson Cancer
Center is one of the largest multidisciplinary breast centers
in the United States, offering comprehensive treatment for all
forms and stages of breast cancer, as well as surgical reconstruction
for mastectomy patients.
M. D. Anderson's Morgan Welch Inflammatory Breast Cancer Research
Program and Clinic is the largest and world’s first clinic
devoted solely to the research, diagnosis and therapy of this
unusual and treatment-resistant form of cancer.
Research and Clinical Achievements
M. D. Anderson…
- Ranks first in the number of grants awarded - including 10
Specialized Programs of Research Excellence (SPORE) grants -
and total amount of grant dollars from the National Cancer Institute.
- Demonstrated in clinical studies that "lumpectomy"
followed by radiation for breast cancer can be as effective
as radical mastectomy, now a standard practice worldwide.
- Demonstrated that measuring cancer cells circulating in the
blood can predict outcomes for patients with advanced breast
cancer, thereby helping to identify patients requiring more
aggressive treatment to improve survival.
- Documented for the first time the difference in sensitivity
to chemotherapy among different genetic subtypes of breast cancer
leading to more effective treatment.
- Played a leadership role in an international trial demonstrating
that raloxifene, like tamoxifen, can prevent or delay the incidence
of breast cancer in high-risk women.
- Pioneered a combined-modality triple treatment strategy for
the successful management of locally advanced inflammatory breast
cancers, now the standard of care.
- Demonstrated the efficacy of Taxol against breast cancer,
now standard treatment.
- Showed that chemotherapy can safely be given after the first
trimester to pregnant women with breast cancer.
- Developed mammography technology and showed that mammography
can detect breast cancer at early, highly curable stages, leading
to adoption of standardized screening mammography.
- Created the nation's largest bone marrow transplantation program
enabling treatment of over 600 patients with high dose chemotherapy
annually.
More Information About M.D. Anderson:
- In the last 60 years, M. D. Anderson has built a worldwide
reputation for excellence in cancer patient care, research,
education and prevention. Read
more...
- 10
Steps Toward Diversity - M. D. Anderson owes much of its
reputation as a world-class cancer center to a culturally
diverse workforce with unique and valuable skills. The Office
of Institutional Diversity (OID) builds on that foundation
with a 10-point initiative to recruit and retain minority
and female employees.
- In 2008, U.S.
News and World Report’s “America’s Best
Hospitals” survey ranked M. D. Anderson as the top
hospital in the nation for cancer care. M. D. Anderson has
achieved the top ranking four times in the past six years
and has ranked as one of the top two hospitals for cancer
care for 19 years, since the magazine began its annual survey
in 1990.
|
